STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES
NASDAQ: GPCR (Structure Therapeutics Inc.)
Last update: 9 hours ago74.92
1.71 (2.34%)
| Previous Close | 73.21 |
| Open | 75.01 |
| Volume | 1,101,916 |
| Avg. Volume (3M) | 1,649,304 |
| Market Cap | 5,292,286,976 |
| Price / Book | 7.45 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -2.58 |
| Total Debt/Equity (MRQ) | 0.92% |
| Current Ratio (MRQ) | 23.29 |
| Operating Cash Flow (TTM) | -134.78 M |
| Levered Free Cash Flow (TTM) | -80.30 M |
| Return on Assets (TTM) | -17.24% |
| Return on Equity (TTM) | -22.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Structure Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | -0.13 |
|
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 3.08% |
| % Held by Institutions | 101.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Janus Henderson Group Plc | 30 Sep 2025 | 4,448,826 |
| Bvf Inc/Il | 30 Sep 2025 | 3,203,917 |
| Casdin Capital, Llc | 30 Sep 2025 | 1,555,000 |
| Ra Capital Management, L.P. | 30 Sep 2025 | 1,517,418 |
| Principal Financial Group Inc | 31 Dec 2025 | 1,284,210 |
| Siren, L.L.C. | 30 Sep 2025 | 1,026,811 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 140.00 (Guggenheim, 86.87%) | Buy |
| Median | 105.00 (40.15%) | |
| Low | 90.00 (Stifel, 20.13%) | Buy |
| 90.00 (HC Wainwright & Co., 20.13%) | Buy | |
| Average | 110.44 (47.41%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 72.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 22 Jan 2026 | 105.00 (40.15%) | Buy | 91.87 |
| Guggenheim | 20 Jan 2026 | 140.00 (86.87%) | Buy | 91.02 |
| HC Wainwright & Co. | 19 Dec 2025 | 90.00 (20.13%) | Buy | 64.94 |
| Citizens | 12 Dec 2025 | 120.00 (60.17%) | Buy | 67.06 |
| Morgan Stanley | 12 Dec 2025 | 125.00 (66.84%) | Buy | 67.06 |
| Jefferies | 11 Dec 2025 | 125.00 (66.84%) | Buy | 67.44 |
| Citigroup | 09 Dec 2025 | 100.00 (33.48%) | Buy | 66.74 |
| Clear Street | 09 Dec 2025 | 99.00 (32.14%) | Buy | 66.74 |
| Stifel | 09 Dec 2025 | 90.00 (20.13%) | Buy | 66.74 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |